Published in Pharm Res on February 01, 1993
Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. AAPS PharmSciTech (2000) 0.91
A history of biopharmaceutics in the Food and Drug Administration 1968-1993. AAPS J (2009) 0.77
Best practices for the development, scale-up, and post-approval change control of IR and MR dosage forms in the current quality-by-design paradigm. AAPS PharmSciTech (2014) 0.76
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother (1984) 4.03
Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet (1992) 2.88
Stability of sodium ampicillin solutions in the frozen and liquid states. Am J Hosp Pharm (1971) 2.69
Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol (1997) 2.35
The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res (1997) 2.28
Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm (2000) 2.14
Complete Sequence and Enhancer Function of the Homologous DNA Regions of Autographa californica Nuclear Polyhedrosis Virus. J Virol (1986) 2.14
Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res (1998) 2.08
Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res (1996) 2.05
Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis (2010) 1.86
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res (1998) 1.66
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther (1997) 1.64
Preoperative chemotherapy and the outcome of liver resection for colorectal metastases. World J Surg (2007) 1.52
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother (1985) 1.46
Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci (2000) 1.45
'Vasoconstriction'--skin blanching--assay for glucocorticoids--a critique. Arch Dermatol (1989) 1.41
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci (2004) 1.41
The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol Cell Biol (2005) 1.40
A multiple-dose pharmacokinetic comparison of naproxen as a once-daily controlled-release tablet and a twice-daily conventional tablet. J Clin Pharmacol (1987) 1.40
Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res (2001) 1.39
Relative bioavailability of a new transdermal nitroglycerin delivery system. J Pharm Sci (1986) 1.39
A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension. Manag Care Interface (2001) 1.38
From genome to vaccine: in silico predictions, ex vivo verification. Vaccine (2001) 1.37
Targeted prodrug design to optimize drug delivery. AAPS PharmSci (2000) 1.36
A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm (1999) 1.35
The effect of keto-analogues of essential amino acids in severe chronic uremia. J Clin Invest (1973) 1.31
Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions. Biochemistry (1998) 1.23
Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology (1988) 1.23
A 40-kilodalton protein binds specifically to an upstream sequence element essential for muscle-specific transcription of the human myoglobin promoter. Mol Cell Biol (1992) 1.22
Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci (1985) 1.21
The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm (1987) 1.20
Moisture sorption kinetics for water-soluble substances. I: Theoretical considerations of heat transport control. J Pharm Sci (1983) 1.19
In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants. Pharm Res (1989) 1.19
In vitro release profiles of clonidine transdermal therapeutic systems and scopolamine transdermal patches. Pharm Res (1989) 1.18
Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res (1996) 1.17
Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev (1996) 1.17
Effect of phenobarbital on theophylline disposition. J Allergy Clin Immunol (1978) 1.16
Prediction of physical aging in controlled-release coatings: the application of the relaxation coupling model to glassy cellulose acetate. Pharm Res (1991) 1.14
Editorial: Digoxin--the regulatory viewpoint. Circulation (1974) 1.13
Influence of physical aging on mechanical properties of polymer free films: the prediction of long-term aging effects on the water permeability and dissolution rate of polymer film-coated tablets. Pharm Res (1991) 1.13
Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev Ind Pharm (1998) 1.11
Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res (2000) 1.09
Pharmacokinetics of trimethoprim and sulfamethoxazole in normal subjects and in patients with renal failure. J Infect Dis (1973) 1.08
Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res (1998) 1.07
Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). J Pharm Sci (2006) 1.07
Characterization of the biochemical properties of recombinant ribonuclease III. Nucleic Acids Res (1990) 1.07
HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci (1996) 1.05
Novel approach to the analysis of in vitro-in vivo relationships. J Pharm Sci (1996) 1.03
Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: increasing the power of bioavailability tests. J Pharmacokinet Biopharm (1979) 1.03
Release performance of a poorly soluble drug from a novel, Eudragit-based multi-unit erosion matrix. Int J Pharm (2001) 1.03
Protein denaturation during freezing and thawing in phosphate buffer systems: monomeric and tetrameric beta-galactosidase. Arch Biochem Biophys (2000) 1.02
Biology of membrane transport proteins. Pharm Res (1995) 1.02
Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res (1993) 1.02
Multiple-dose ciprofloxacin dose ranging and kinetics. Clin Pharmacol Ther (1985) 1.00
Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy. Clin Pharmacol Ther (2011) 1.00
Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. J Control Release (1999) 0.98
In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine. Gene Ther (1998) 0.98
Stimulus selectivity and state dependence of activity in inferior temporal cortex of infant monkeys. Proc Natl Acad Sci U S A (1991) 0.98
A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem (2000) 0.98
Role of integrin expression in adenovirus-mediated gene delivery to the intestinal epithelium. Hum Gene Ther (1998) 0.98
Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res (1991) 0.98
Solubility of nonelectrolytes in polar solvents II: solubility of aliphatic alcohols in water. J Pharm Sci (1974) 0.97
Solubility of nonelectrolytes in polar solvents IV: nonpolar drugs in mixed solvents. J Pharm Sci (1976) 0.96
Time-dependent oral absorption models. J Pharmacokinet Pharmacodyn (2001) 0.95
Membrane permeability parameters for some amino acids and beta-lactam antibiotics: application of the boundary layer approach. J Theor Biol (1988) 0.95
A new method of dissolution in vitro, the "Bio-Dis" apparatus: comparison with the rotating bottle method and in vitro: in vivo correlations. J Pharm Sci (1991) 0.95
Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J Pharm Sci (2000) 0.95
Human proton/oligopeptide transporter (POT) genes: identification of putative human genes using bioinformatics. AAPS PharmSci (2000) 0.95
Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res (1990) 0.94
Viscoelastic properties of polyacrylic acid gels in mixed solvents. Pharm Res (1992) 0.94
Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharm Res (1992) 0.93
In vitro release of hydrocortisone from topical preparations and automated procedure. Pharm Res (1991) 0.93
Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig Dis Sci (1987) 0.93
Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. J Pharmacol Exp Ther (2001) 0.93
Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharm Res (1988) 0.93
Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm (1998) 0.93
Analysis of models for determining intestinal wall permeabilities. J Pharm Sci (1980) 0.92
Scaleup of oral extended-release dosage forms. Pharm Res (1993) 0.92
Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. J Pharm Sci (1989) 0.92
Passive and carrier-mediated intestinal absorption components of captopril. J Pharm Sci (1988) 0.92
Characterization of the oral absorption of beta-lactam antibiotics. II. Competitive absorption and peptide carrier specificity. J Pharm Sci (1989) 0.92
Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci (1986) 0.92
Mechanism of drug release from an acrylic polymer-wax matrix tablet. J Pharm Sci (1994) 0.92
Effects of humidity and temperature on in vitro dissolution of carbamazepine tablets. J Pharm Sci (1993) 0.91
Calculation of the aqueous diffusion layer resistance for absorption in a tube: application to intestinal membrane permeability determination. Pharm Res (1991) 0.91
Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci (1982) 0.90
CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci (1999) 0.90
Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables. Eur J Pharm Biopharm (2000) 0.90
Nonfatal rabies in dogs: experimental studies and results of a survey. Am J Vet Res (1971) 0.90
Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm Res (1997) 0.90
Modulated drug release using iontophoresis through heterogeneous cation-exchange membranes. 2. Influence of cation-exchanger content on membrane resistance and characteristic times. J Pharm Sci (1994) 0.90
Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharm Res (1998) 0.90
Genetic polymorphism in eight Chilean strains of the carotenogenic microalga Dunaliella salina Teodoresco (Chlorophyta). Biol Res (2001) 0.89
Mixture experimental design in the development of a mucoadhesive gel formulation. Pharm Res (1991) 0.89
Long-term survival of free fat grafts in muscle: an experimental study in rats. Aesthetic Plast Surg (1996) 0.89